Patents by Inventor David C. Myles

David C. Myles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030114450
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Application
    Filed: August 5, 2002
    Publication date: June 19, 2003
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Publication number: 20030109682
    Abstract: Cytotoxin-targeting molecule conjugates comprising cytotoxin and an antibody, growth factor, or polysaccharide together with a pH-sensitive or redox potential-sensitive linker. Novel ansamitocins and recombinant genes and organisms that produce them. The use of the described conjugates in the treatment of cancer and other hyperproliferation diseases.
    Type: Application
    Filed: September 3, 2002
    Publication date: June 12, 2003
    Inventors: Daniel Santi, David C. Myles, Brian Metcalf, C. Richard Hutchinson, Gary Ashley
  • Publication number: 20020137939
    Abstract: Compounds of formula IA and IB are new 1
    Type: Application
    Filed: August 31, 2001
    Publication date: September 26, 2002
    Inventors: Paul A. Renhowe, Daniel Chu, Rustum S. Boyce, Zhi-Jie Ni, David Duhl, Effie Tozzo, Kirk Johnson, David C. Myles
  • Publication number: 20020128213
    Abstract: The present invention provides novel sixteen-membered macrolide compounds that are useful as anti-infective agents or as intermediates thereto. The present invention also provides methods for the preparation of these compounds, and methods and formulations for their use. In one aspect of the present invention, sixteen-membered macrolide possessing a side chain Z are provided where Z is aliphatic, aryl, alkylaryl, halide, ═NOR3, ═NNHR3, or —W—R3 where W is O, S, NC(═O)R4, NC(═O)OR4, NC(═O)NHR4 or NR4 where R3 and R4 are each independently hydrogen, aliphatic, aryl or alkylaryl. In another aspect of the present invention, bicyclic compounds are provided where one of the cyclic-components is a sixteen-membered macrolide and the other is a cyclic moiety whose cyclic structure is formed by between 3 and 10 atoms. In another aspect of the present invention, sixteen-membered macrolide compounds that bind to the domain II region of the 23S RNA are provided.
    Type: Application
    Filed: September 24, 2001
    Publication date: September 12, 2002
    Inventors: Leonard Katz, Gary Ashley, Mark A. Burlingame, Steven D. Dong, Hong Fu, Yong Li, David C. Myles
  • Publication number: 20020052028
    Abstract: The present invention relates to compounds made by a subset of modules from one or more polyketide synthase (“PKS”) genes that are used as starting material in the chemical synthesis of novel molecules, particularly naturally occurring polyketides or derivatives thereof. The biologically derived intermediates (“bio-intermediates”) generally represent particularly difficult compounds to synthesize using traditional chemical approaches due to one or more stereocenters. In one aspect of the invention, an intermediate in the synthesis of epothilone is provided that feeds into the synthetic protocol of Danishefsky and co-workers. In another aspect of the invention, intermediates in the synthesis of discodermolide are provided that feed into the synthetic protocol of Smith and co-workers.
    Type: Application
    Filed: August 9, 2001
    Publication date: May 2, 2002
    Inventors: Daniel Santi, Gary Ashley, David C. Myles